Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI)

Biotechnology Research • Copenhagen, Capital Region of Denmark, Denmark • 11-20 Employees

Company overview

Headquarters	Blegdamsvej 3b, Copenhagen, Capital Region of Denmark 2200, DK
Websites	ku.dk niviresearch.ku.dk
NAICS	541714
Keywords	Infectious Diseases, Vaccines, Immunity, Vaccine Development, Airborne Diseases, Airborne Epidemics, Airway Delivery, Airway Immunity, Airway Immunology, Respiratory Pathogens, Vaccine Platforms
Founded	2024
Employees	11-20
Socials

Key Contacts at Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI)

Hocine Mankouri

Interim Managing Director Of Nivi-Development

Kara Aves

Director, External R&D

Jane Ellen Elvekjær

Pa To Ceo/Executive Director, Senior Consultant

Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) Email Formats

Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) uses 1 email format. The most common is {2char} (e.g., {2char}@novonordisk.com), used 100% of the time.

Format	Example	Percentage
{2char}	{2char}@novonordisk.com	100%

About Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI)

The Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) brings together leading experts in airway immunology and vaccine development to tackle some of the deadliest respiratory pathogens. The aim is to revolutionize and accelerate vaccine development by bridging the gap between academic research and industry innovation. NIVI is a partnership between the University of Copenhagen and the Novo Nordisk Foundation. The initiative is comprised of two distinct entities: NIVI Research Center is a state-of-the-art academic research center anchored at the Department of Immunology and Microbiology at the University of Copenhagen. NIVI-R directs the research, discovery and educational aspects of the NIVI initiative. For more information: https://niviresearch.ku.dk/about-center/ NIVI Development is a limited liability company owned by the Novo Nordisk Foundation. NIVI-D facilitates the initiatives translational efforts by providing industry-level expertise in vaccine development and clinical testing. NIVI’s VISION & MISSION Vision: To prevent airborne epidemics and limit the spread of anti-microbial resistance through the development of novel vaccines. Mission: To generate knowledge on host immunity, host-pathogen interactions, and vaccine technologies. And to translate this knowledge into vaccines that provide robust, durable and broad immunity against respiratory pathogens.

Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) revenue & valuation

Annual revenue	$1,026,660
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$3,300,000
Total funding	No funding

Employees by Management Level

Total employees: 11-20

Seniority

Employees

Entry

C-Suite

Director

Employees by Department

Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) has 8 employees across 5 departments.

Departments

Number of employees

Funding Data

Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) has never raised funding before.

Frequently asked questions

Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) is located in Copenhagen, Capital Region of Denmark, DK.

Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) was founded in 2024, making it 2 years old. The company has established itself as a significant player in its industry over this time.

Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.